| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Novo Nordisk faces board changes, investor friction and bold M&A moves as leadership pushes to regain momentum in the obesi...
-SEC Filing-SEC Filing
Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscapeCom...
Pfizer plans to sell its remaining BioNTech stake through a $508 million block trade, ending a profitable Covid-19 vaccine part...
https://www.bloomberg.com/news/articles/2025-11-13/pfizer-looks-to-sell-stake-in-pandemic-vaccine-partner-biontech
Novo Nordisk's Coramitug cut NT-proBNP levels and was well tolerated in a Phase 2 ATTR-CM trial, paving the way for its Pha...
Novo Nordisk shares are trading higher on Tuesday. The company recently lost its bidding war for Metsera Inc.